Replimune Group, Inc. (REPL) — SEC Filings

Latest SEC filings for Replimune Group, Inc. (REPL), explained in plain English.

Sentiment Overview: 2 bullish, 2 bearish, 45 neutral, 1 mixed

Recent Filings (50)

• Baker Bros. Adjusts Replimune Group Holdings — 4 · 2026-04-07T21:15:19-04:00 [neutral] Risk: medium
  On April 1, 2026, Baker Bros. Advisors LP, through Julian Baker and Felix Baker, reported a change in beneficial ownership of securities for Replimune Group, In
• Replimune Group Insider Reports Securities Ownership Change — 4 · 2026-04-07T21:10:52-04:00 [neutral] Risk: low
  On April 1, 2026, Philip Astley-Sparke, a reporting person associated with Replimune Group, Inc., reported a change in beneficial ownership of securities. The f
• Replimune Group Inc. (CLIP) Ownership Change Reported — 4 · 2026-04-07T21:09:49-04:00 [neutral] Risk: low
  On April 1, 2026, Balachandran Madhavan reported a change in beneficial ownership of securities for Replimune Group, Inc. The filing, dated April 7, 2026, detai
• 4 Filing — 4 · 2026-04-07T21:09:02-04:00 [neutral]
• Replimune Group Inc. Insider Ownership Update — 4 · 2026-04-07T21:08:44-04:00 [neutral] Risk: low
  On April 1, 2026, Pucci Paolo reported a change in beneficial ownership of securities for Replimune Group, Inc. The filing details transactions related to his h
• Replimune Group Inc. (CLIP) Insider Ownership Change — 4 · 2026-04-07T21:08:32-04:00 [neutral] Risk: low
  On April 1, 2026, Joseph P. Slattery, a reporting person for Replimune Group, Inc., reported a change in beneficial ownership of securities. The filing details
• Replimune Group Files 8-K on Financials — 8-K · 2025-11-06T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Replimune's Losses Widen Amid Soaring R&D, SG&A Costs — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  Replimune Group, Inc. reported a significant increase in net loss for the three and six months ended September 30, 2025, primarily driven by higher operating ex
• Replimune Group Files 8-K — 8-K · 2025-10-20T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on October 20, 2025, reporting on other events and financial statements. The filing details the company's principal executive
• Replimune to Acquire Remaining Shares — 8-K · 2025-09-18T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. announced on September 16, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of the company not alre
• Replimune Group Files 8-K on Shareholder Votes and Disclosures — 8-K · 2025-09-04T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on September 4, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
• Replimune Group Files 8-K on Financials — 8-K · 2025-08-07T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
• Replimune Continues R&D Spend, No Revenue in Q1 2026 — 10-Q · 2025-08-07T00:00:00.000Z [neutral] Risk: high
  Replimune Group, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with the prior year, as it remains a clinical-stage biotechnology comp
• Replimune Sets Virtual Annual Meeting for Sept. 3, Urges Proxy Votes — DEF 14A · 2025-07-25T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. (REPL) filed a DEF 14A proxy statement on July 25, 2025, for its Annual Meeting of Stockholders scheduled for September 3, 2025, at 11:30
• Replimune Group Files 8-K — 8-K · 2025-07-22T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on July 22, 2025, reporting on events that occurred on July 21, 2025. The filing indicates disclosures related to Regulation
• Replimune Group Files 8-K for Regulation FD Disclosure — 8-K · 2025-06-24T00:00:00.000Z [neutral] Risk: low
  On June 24, 2025, Replimune Group, Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No specific financia
• Replimune Group Files 8-K on Operations — 8-K · 2025-05-22T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on May 22, 2025, reporting on its results of operations and financial condition. The filing details financial statements and
• Replimune's Net Loss Widens to $240.5M Amid R&D Push — 10-K · 2025-05-22T00:00:00.000Z [bearish] Risk: high
  Replimune Group, Inc. reported no revenue for the fiscal year ended March 31, 2025, consistent with its clinical-stage biotechnology status. The company posted
• Replimune Announces Executive and Board Changes — 8-K · 2025-03-07T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. announced on March 5, 2025, the departure of Dr. Robert L. Kirk as Chief Medical Officer and the appointment of Dr. Philip J. Kantoff as i
• Replimune Group Files 8-K on Financials — 8-K · 2025-02-12T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on February 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Replimune Group Files Q3 2024 10-Q — 10-Q · 2025-02-12T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. filed its 10-Q for the period ending December 31, 2024. The company, based in Woburn, MA, operates in the biological products sector. This
• Replimune Group Files 8-K — 8-K · 2025-01-22T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on January 22, 2025, reporting other events and financial statements/exhibits. The filing date indicates the earliest event r
• Replimune Group Files 8-K/A Amendment — 8-K/A · 2024-12-04T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K/A on December 4, 2024, to amend a previous filing. This amendment specifically relates to the financial statements and exhibi
• Replimune Group Files 8-K — 8-K · 2024-11-27T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on November 27, 2024, reporting other events and financial statements. The filing date for the report was November 25, 2024.
• Replimune Strikes $1.85B+ Oncology Deal — 8-K · 2024-11-26T00:00:00.000Z [bullish] Risk: medium
  Replimune Group, Inc. announced on November 25, 2024, that it has entered into a strategic collaboration with a major pharmaceutical company. This collaboration
• Replimune Group Files 8-K — 8-K · 2024-11-21T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on November 21, 2024, to report on other events and financial statements. The filing does not contain specific details on new
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Replimune Group Files 8-K on Financials — 8-K · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing details financial statements
• Replimune Reports Q2 Loss, R&D Expenses Rise — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss of $101.7 million for the three months ended Sept
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-04T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-10-07T00:00:00.000Z [neutral]
• Replimune Group Reports on Shareholder Vote Matters — 8-K · 2024-09-05T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on September 5, 2024, reporting on matters submitted to a vote of security holders on September 4, 2024. The filing details t
• Replimune to Acquire Aura BioSciences for $350M — 8-K · 2024-08-08T00:00:00.000Z [mixed] Risk: medium
  Replimune Group, Inc. announced on August 8, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of Aura BioSciences, Inc. f
• Replimune Group Files Q1 FY25 10-Q — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company, based in
• Replimune Files Definitive Proxy Statement for 2024 Shareholder Meeting — DEF 14A · 2024-07-19T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed its definitive proxy statement on July 19, 2024, for its annual meeting of stockholders scheduled for September 4, 2024. The filing
• SC 13G/A Filing — SC 13G/A · 2024-07-10T00:00:00.000Z [neutral]
• Replimune Group Enters Definitive Agreement, Discloses Equity Sales — 8-K · 2024-06-13T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. announced on June 12, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
• Replimune Closes $300M Public Offering — 8-K · 2024-06-06T00:00:00.000Z [bullish] Risk: medium
  Replimune Group, Inc. filed an 8-K on June 6, 2024, to report on the closing of its previously announced underwritten public offering. The company successfully
• Replimune Group Files 8-K with Corporate Details — 8-K · 2024-06-03T00:00:00.000Z [neutral] Risk: low
  Replimune Group, Inc. filed an 8-K on June 3, 2024, reporting other events and financial statements. The filing details the company's principal executive office
• Replimune Group Files 8-K on Financials — 8-K · 2024-05-16T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. filed an 8-K on May 16, 2024, reporting on its results of operations and financial condition. The filing details financial statements and
• Replimune Group, Inc. Files 2024 10-K — 10-K · 2024-05-16T00:00:00.000Z [neutral] Risk:
  Replimune Group, Inc. (REPL) filed a Annual Report (10-K) with the SEC on May 16, 2024. Filed 10-K for the fiscal year ended March 31, 2024. Company is in the B
• SC 13G/A Filing — SC 13G/A · 2024-04-10T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-04-10T00:00:00.000Z [neutral]
• Replimune Appoints New CMO and CDO, Chief Medical Officer Departs — 8-K · 2024-03-26T00:00:00.000Z [neutral] Risk: medium
  Replimune Group, Inc. announced on March 21, 2024, the appointment of Dr. Philip Astley-Sparke as Chief Medical Officer and Dr. Robert Burns as Chief Developmen
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]